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ABSTRACT 
Quantum dots are semiconducting nanocrystals that exhibit extraordinary optical properties. 
QD have shown higher photostability compared to standard organic dye type probes. 
Therefore, they have been heavily explored in the biomedical field. This review will discuss 
the different approaches to synthesis, solubilise and functionalise QD. Their main biomedical 
applications in imaging and photodynamic therapy will be highlighted. Finally, QD 
biodistribution profile and in vivo toxicity will be discussed.  
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1. QD history and chemical composition 
In 1973, Leo Esaki, a Japanese physicist won the Nobel Prize in physics for the development 
of semiconductor devices, and for his early concept of ‘‘artificial solids’’ [1]. The 
development of different types of semiconductor systems (quantum wells, quantum wires and 
quantum dots) was tremendously expanded in the 1980s. Semiconductor QD are 1-10 nm 
nanoparticles consisting mainly of a semiconductor core with or without an inorganic 
passivation shell usually made of zinc-sulfide (ZnS). The shell is generally used to protect the 
QD core from oxidation and photolysis [2;3] and minimise the associated-toxicity related to 
the release of Cd+2 ions [4]. 
 
QD were initially prepared in 1982 for use as probes to investigate the surface kinetics [5]. It 
was found that the cadmium-sulfide (CdS) QD fluorescence and quantum yield were 
sensitive to different surface species. Oxidisable species were poor fluorescence quenchers, 
while reducible species were excellent quenchers. Species without an appropriate redox 
capacity did not affect the QD fluorescence properties. Much progress has also been made in 
the synthesis and characterisation of QD [6]. The first highly crystalline and monodispersed 
cadmium-selenide (CdSe) QD published by the Bawendi group, were synthesised in a hot 
coordinating solvent [7]. This was followed by improving the QD photostability by 
passivating their surface with different semiconducting materials [3]. During all these 
developments, organic QD were mainly used in physics to design transistors, solar cells and 
light-emitting diode (LEDs) [8;9]. In 1998, the first synthetic approaches to water soluble QD 
were published [10;11], highlighting the potential use of QD in the biomedical field.  
 
Currently QD are not only composed of CdS or CdSe but of many different semiconducting 
materials derived from the II -VI elemental groups (e.g. zinc-sulfide [ZnS], zinc-selenide 
[ZnSe], and cadmium-telluride [CdTe]); or III-V elemental groups (indium phosphate [InP], 
indium arsenate [InAs], gallium arsenate [GaAs] and gallium nitride [GaN]), or IV-VI 
elemental groups (e.g. lead-selenide [PbSe], lead-sulfide [PbS]) [12-15]. In addition to the 
huge advances in semiconductor synthesis, novel QD such as CdTe/CdSe (core/shell), 
CdSe/ZnTe (core/shell) [16] and cadmium-free QD, Mn doped ZnSe [17;18] have also been 
developed. 
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2. QD fluorescence characteristics 
QD are fluorescent nanoparticles that offer distinct spectrofluorometric advantages over 
traditional fluorescent organic molecules (e.g. fluorescein, Nile red) [10;12]. Traditional 
organic dyes exhibit narrow excitation peaks, where a narrow range of wavelengths can be 
used for excitation. Moreover, they have asymmetric emission spectra with red-tailing. On 
the other hand, QD reveal broad excitation spectra, allowing excitation over a wide range of 
wavelengths. They also exhibit symmetric and narrow emission peaks. Therefore, multiple 
QD with different sizes can be excited using a single wavelength shorter than their emission 
wavelengths. Since the emission spectrum is narrow, fluorescence signals can be separated 
and detected simultaneously, to achieve multiplexing imaging [19-21]. Apart from absorption 
and emission characteristics, inorganic semiconductor QD have shown high quantum yield, 
higher resistance to photobleaching and longer fluorescence lifetime compared to organic 
QD, which makes them suitable for continuous tracking over a prolonged period [22]. The 
most striking property of QD is the massive changes in the QD optical characteristics as a 
function of size [8]. As the QD size increases, the emission shifts towards longer 
wavelengths. Such phenomenon is attributed to the ‘‘quantum confinement’’ effect, which is 
observed with the optical characteristics of semiconductors smaller than 10-20 nm, and from 
which QD were named [8]. 
 
3. Solubilisation and ligand conjugation 
QD can either be prepared by water-based synthetic methods [23;24] or in non-polar organic 
solvents [7;25]. The latter approach produces monodispersed QD with a range of emission 
colour ranging from ultraviolet to infrared, compared to QD prepared immediately in aqueous 
solution [26-28]. However, QD synthesised in organic solvents contain organic shells that 
compromise their water solubility and consequently their compatibility with the biological 
milieu. Many strategies are being developed to overcome this limitation. Several hydrophilic 
ligands have been utilised to exchange the hydrophobic trioctylphosphine oxide (TOPO) coat 
on the QD surface with hydrophilic moieties (Figure 1, left).  including; (i) thiol-containing 
molecules, such as mercaptoacetic acid (MAA), dihydrolipoic acid (DHLA) [29] and 
mercaptopropyltris (methoxy) silane (MPS) [30], (ii) peptides [31],  (iii) dendron [32;33] and 
(iv) oligomeric phosphine [34]. In spite of maintaining small sizes, this method tends to cause 
QD aggregation and decreases the fluorescence efficiency [35-40]. Also, as a labile ligand 
detaches from QD surface, QD-induced toxicity will increase correspondingly due to 
exposure to the QD core [41;42]. 
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Figure 1 
 
The other alternative approach is driven by hydrophobic interactions between the organic QD 
surface and the hydrophobic domain of amphiphilic molecules (Figure 1, right). Embedding 
or encapsulating organic QD into phospholipid micelles [22;43], and amphiphilic diblock or 
triblock copolymers [39;44] was found to increase QD diameter significantly, but more 
importantly to preserve QD photostability, colloidal stability and enable QD application to 
physiological conditions without the release of the toxic Cd+2 ions [44].  
 
Bioactive ligands have been attached to QD surfaces to enable QD specific binding and 
targeting or to design multimodal probes. Several approaches have been investigated 
including non-covalent, electrostatic adsorption onto the QD surface [29], covalent 
attachment [45] and streptavidin-biotin linking [46]. So far, QD surface has been decorated 
with different ligands such as proteins [47], antibodies [44;48;49], peptides [50-52], 
endosome-disruptive polymers [53], aptamers [54], DNA  [22;55-57], cell penetrating 
peptides [58-63], radionuclides [64;65] and magnetic resonance imaging (MRI) agents [66].  
 
4. Biomedical applications 
 QD are being explored as potential imaging agents primarily in fluorescence-based 
diagnostic applications [22;45;67]. Unlike organic fluorophores, QD have distinctive broad 
excitation spectra and narrow emission peak, which can be easily used for multiplexing 
imaging [19-21]. In addition, QD have outstanding fluorescence properties that resist 
photobleaching over time, which is suitable to label cells in vitro [14;21;22;68] and organs in 
vivo  [e.g. RES [67;69], blood vessels [50;70], lymph nodes [71-74] and solid tumours 
[44;52;75;76]]. Recently, DNA conjugated to the QD surface has been described as a 
promising tool in fluorescent in situ hybridisation (FISH) where gene abnormalities in cells 
could be identified [22;55-57;77]. 
 
More interestingly, multimodal imaging probes can be engineered by combining QD with 
magnetic [66] or paramagnetic [78] agents, as well as radioactive isotopes [64;65;79]. This 
significantly improves the sensitivity and the resolution of the imaging procedures in vivo 
[80]. Contrary to diagnostic agents for MRI and positron emission tomography (PET), QD 
can provide visual guidance during surgery or diagnosis. In addition, these electron-dense QD 
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can be easily visualised in the target tissue at a microscopic level under the fluorescence and 
transmission electron microscopes [14;81]. Moreover, quenching QD fluorescence by 
conjugating fluorescence quenchers such as gold nanoparticles or nitroxide [82;83] to the QD 
surface can provide information about the QD environment, where cleavage of the quencher 
at the target tissue (e.g. low pH, enzymes) restores QD fluorescence [68]. 
 
Another approach to construct multifunctional devices has been described by combining the 
QD optical characteristics with therapeutic agents. Samia et al. and others have reported the 
promising potential of QD in photodynamic therapy (PDT) since QD energy can activate 
surface-conjugated photosensitisers (PS) [84-90]. In addition, the optical characteristics of 
QD can be easily manipulated to match the PS excitation wavelength by changing the QD 
size and composition. All above applications will be discussed below in more details. 
 
Imaging agent: Long-term cell tracking can be very important in studies such as cell lineage 
and differentiation (e.g. embryogenesis, stem cells, transplanted cells) [19;22], also, in 
metastatic cancer [20;21;91]. Fluorescent cell labelling is a promising tool to track cells [45], 
many approaches have been developed to label cells either by microinjection with organ 
fluorophores or by transfecting the cells with reported genes that code for fluorescent proteins 
like GFP [92]. Conventional fluorophores have broad emission spectra which make it 
difficult to distinguish different probes administered concurrently. Unlike organic 
fluorophores, QD have distinctive broad excitation spectra and narrow emission peak, which 
can be easily used for multiplexing imaging [19-21], also, QD have outstanding fluorescence 
properties that resist photobleaching over time, they are good candidate to label and track 
cells in vitro [14;21;22;68] and in living animal [20;21;91]. 
For in vivo applications, in 2002 Dubertret and his colleagues, firstly introduced the 
outstanding fluorescence properties of biocompatible PEG-coated QD injected into Xenopus 
embryo [22]. QD have been used also as tool to study embryogenesis in zebrafish embryo  
and angiogenesis in chick CAM model [81]. In addition, QD have been used for imaging 
larger animals such as mice and pigs [93]. QD have been explored as an imaging agent for 
the lymph nodes [71-74], reticuloendothelial systems (RES) [67;69;94]. Moreover, 
decorating the QD surface with hydrophilic polymers could escape the RES and can be 
targeted to other organs, such as tumour and angiogenic blood vessels [44;50;52;70;76].  
 7 
Several groups could target QD to tumours in living animals. This could be achieved by 
passive and active targeting as well as direct intratumuoral injection. For passive targeting, 
the nanoparticles should have nanometer size (≤ 100nm) and exhibit long blood circulation to 
accumulate preferentially in the tumour which is in agreement with QD characteristics [44]. 
Moreover,  Gao and his colleagues targeted tricoplymer-coated QD to solid prostate tumour 
model in living mice [44], Akerman et al. and Cai et al. actively targeted peptide-coated QD 
to the tumour vasculatures and lymphatic vessels [50;52]. QD also have been targeted to 
hepatoma xenograft in nude mice [76]. Balluo et al . could  label M21 humanmelanoma and 
MH-15 mouse teratocacinoma solid  xenograft and sentinel lymph nodes in living mice by 
direct intratumoural injection [95].         
Organic fluorophores have been widely used for optical imaging, despite rapid 
photobleaching, the excitation wavelength is mainly in the visible light region, where light 
absorption by the tissue is still problematic for imaging thick sections and whole living 
animals. Two-photon excitation microscopy has been used heavily in tumour detection 
studies as it exhibits lower sample scattering and stronger sample penetration than one-
photon excitation [20;21;70;75] where thick sections can be visualised with high resolution. 
QD are a promising tool for optical imaging as they are good labels for multiphoton 
microscopy [75]. Larson et al. could successfully image the blood vessels in living mice into 
the after QD intravenous administration using multiphoton excitation microscopy, showing 
that higher contrast and imaging depth can be obtained at a lower excitation power compared 
to conventional organic dyes [70]. More interestingly, Voura et al. could track QD-labelled 
B16 melanoma metastatic cell extravasation in the lung after systemic administration in 
C57Bl6 mice using the same technique [21]. 
 Near infrared (NIR) QD are a new class of QD used as imaging agents. They have shown 
better deep tissue imaging as minimum tissue light absorption occurs in this region [81]. In 
the last few years, Frangioni group has studied NIR QD extensively as imaging agent for 
sentinel lymph nodes (SLN) mapping in small animals and large animals. Kim et al. were the 
first to observe the rapid QD accumulation in the axillary lymph nodes after intradermal 
injection [93]. So far, successive researches have been carried out to mapped SLN of the 
pleural space [71], oesophagus [72], lung [73] and gastrointestinal tract [74]. Interestingly,  
similar results were obtained by Ballou and his colleagues following intraumoural injection 
of QD with different surface charges [95].  NIR QD were found superior to vital blue dye and 
99mTc colloids [71] since 15-20nm QD were uptaken within 5 minutes by SLN post injection, 
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and with detectable fluorescence signals up to few centimetres due to low tissue background 
in the NIR region, also, they are more selective to the first draining lymph node compared to 
other diagnostics that migrate to distant nodes [71;93]. Therefore, QD can be a promising tool 
for real-time intraoperative optical imaging which helps in correctly locating the sentinel 
lymph nodes or small metastatic solid tumour, to remove any tissue affiliated with the tumour 
[96]. The latter demonstration suggests that NIR imaging of QD can significantly improve 
tumour removal surgery and reduce the tumour recurrence in human. 
Self-illuminating QD for in vivo imaging have been successfully described [97]. This new 
class of QD, based on bioluminescence resonance energy transfer (BRET), where the 
fluorescence emission of luciferase-QD conjugate occurs only in the presence of luciferase 
substrate (coelenterazine). Compared to existing QD, self-illuminating QD showed higher 
sensitivity in both superficial and deep tissue in living animals since tissue autofluorescence 
is minimal in the absence of external excitation source. 
Dual-modality contrast agent: Combining the optical imaging with existing magnetic 
resonance imaging (MRI) diagnostic agents can significantly improve the sensitivity and the 
resolution for in vivo imaging [80]. Nanocomposite made up of iron oxide nanoparticle and 
CdSe/ZnS QD have shown dual magneto-optical properties that can be detected by both MRI 
and fluorescence microscopy [66;98]. Mulder and his colleagues reported conjugation of 
gadolinium to PEG- QD surface which improved the microscopic resolution of MRI [66;99]. 
For multimodal detection, the surface of these nanoparticles was functionalised with different 
bioactive molecules such as RGD peptide to actively target the blood vessels or with Annexin 
A5 protein to detect apoptotic cells in vivo at both microscopic and macroscopic levels. 
Interestingly, QD- iron oxide nanoparticle distribution inside the body was evaluated by MRI. 
Moreover, quenching QD fluorescence by conjugating fluorescent quencher, such as gold 
nanoparticles or nitroxide [82;83] to the QD surface can be useful in providing information 
about their environment, where cleavage of the surface ligands at the target tissue (e.g. low 
pH, enzymes) will restore QD fluorescence.  
Morgan et al. reported a novel CdMnTe/Hg QD having dual electron paramagnetic resonance 
(EPR) and fluorescence imaging properties as Mn+2 has strong EPR signals [78]. These QD 
were successfully used as fluorescent and angiogenic (blood vessels and heart) contrast agent 
in living mice after systemic administration. Michalet et al. described previously 64Cu 
radioactive- QD hybrids where QD targeting and biodistribution can be easily tracked by 
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fluorescence imaging and can be quantified in living mice using micro-positron emission 
tomography (microPET) [67]. Since QD are electron dense they can also be easily visualised 
in the target tissue using transition electron microscopy. 
Photodynamic therapy: QD have a wide surface area where different diagnostics and 
therapeutics such as photosensitiser (PS) can be conjugated to the surface. Samia et al. and 
others have reported using QD in photodynamic therapy (PDT) [84;85;88], since their energy 
can be transferred to the PS. QD have tunable emission spectra which is ranging from UV to 
near infra-red which exhibits better tissue penetration, in contrast to visible emission for most 
conventional  PS (e.g. Photofrin). Moreover, QD optical characteristics can be manipulated 
to match the PS excitation wavelength by changing the QD size and composition. 
Samia and her colleagues reported for the first time, the excitation of poorly soluble 
phthalocyanine PS conjugated to QD surface by fluorescence resonance energy transfer 
(FRET). Thereafter, Tsay et al. successfully conjugated Rose Bengal and Chlorin e6 to 
peptide- coated QD [100]. These conjugates were hydrophilic in contrast to previous studies 
[84;85]. Furthermore, QD-Dopamine conjugates were found to reduce the cell viability of the 
cancer cells upon exposure to UV source, as singlet oxygen species were generated [89].      
Bakalova et al. observed that anti-CD antibodies functionalised QD incubated with leukaemia 
cells and conventional PS (trifluoperazine and sulfonated aluminium phthalocyanine) 
sensitised the tumour cells after UV radiations and potentiated the cytotoxicity of PS [90]. 
Bakalova and his colleagues suggested different mechanisms for QD as PS that collectively 
will induce tumour cell apoptosis and death [86]. Despite low QD ability for singlet oxygen 
formation compared to classical PS [84], the high photostability can allow repetitive 
exposures for the cancer cells to the excitation source to improve the QD cytotoxicity. 
 
5. QD biodistribution and pharmacokinetics in vivo 
The effect of surface coating on QD blood circulation and organ biodistribution was first 
studied by Ballou et al. [69]. Polyacrylic acid-coated QD (PAA-QD) conjugated to low 
molecular weight PEG (750 Da) and intravenously injected into nude mice exhibited short 
blood circulation half-life (t1/2 < 12 min) with predominant uptake by the liver, spleen, lymph 
nodes, and bone marrow. Decorating the same QD with PEG5000 significantly increased the 
blood t1/2 to 3 hrs with less liver, spleen and lymph node uptake [69]. Similar studies by other 
groups showed that 15-20 nm QD coated with PEG5000 exhibited long t1/2 of 5-8 hrs 
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[44;52;101;102]. In all these reports, the QD biodistribution was qualitatively determined 
based either on QD fluorescence in tissue sections using fluorescence and confocal 
microscopy or whole body fluorescence imaging of living animals. Fischer et al. described 
the first quantitative biodistribution study of QD by detecting the Cd atoms in the blood and 
organs of rats injected intravenously with QD [94]. Table 1 summarises the in vivo studies 
performed with QD, several of which have been published using radiolabelled QD 
[65;79;103]. 
 
QD have also been explored for tumour imaging by applying a surface coating that 
maintained QD small size and extended their blood circulation. QD were able to accumulate 
in tumour sites following systemic administration; though this accumulation was increased by 
attaching targeting ligands to the QD surface [44;50]. Akerman et al. previously showed that 
F3 peptide-coated QD and LyP-1 peptide-coated QD specifically bound to the blood and the 
lymphatic vasculatures of MDA-MB-435 human breast carcinoma xenograft following 
intravenous administration [52]. Gao et al. targeted C4-2  human prostate cancer xenograft 
using prostate-specific membrane antigen-QD (PSMA-QD) [44]. Similarly, Cai et al. imaged 
the tumour vasculature of U87MG human glioblastoma xenografts implanted subcutaneously 
in mice using RGD-QD [50]. In order to quantify the targeting efficiency of QD, tumour 
accumulation was evaluated using a dual-function PET/near infrared (NIR) fluorescence 
probe obtained by conjugating 64Cu isotope to NIR QD. Tumour accumulation of the RGD-
QD was 4% of injected dose per gram tissue (ID/g) compared to less than 1% ID/g with non-
targeted QD [64]. Diagaradjane et al. demonstrated three different phases of tumour 
accumulation for epidermal growth factor-QD (EGF-QD) using a colorectal HCT116 
xenograft model, which highly expresses EGF receptor (EGFR) [51]. Immediately after 
systemic administration, both EGF-QD and non-targeted QD (3 min post injection) influxed 
to the tumour. This phase was followed by the clearance phase, where the two types of QD 
were cleared from the tumour interstitium between 3-60 min post-injection. Next, a steady 
increase in EGF-QD fluorescence in the tumour was observed between 1-6 hrs, reflecting 
receptor-specific binding and internalisation. In contrast, QD without the EGF peptide did not 
accumulate in the tumour tissue during this period. These observations suggest that the 
increase in tumour fluorescence over time was due to EGFR-specific binding and 
internalisation of the EGF-QD.  
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There has been a growing concern regarding QD elimination from the body, since QD 
accumulation can potentiate increased toxicity. Ballou et al. previously reported retention of 
QD in the liver, lymph nodes, and bone marrow in mice up to several months [69]. In the 
same study, relocalisation of QD from the liver to the intestine content was described based 
on fluorescence imaging of dead animals, suggesting QD faecal excretion. Contrary to this 
report, others showed slow degradation of inorganic QD in mice and rats with no urine or 
faecal elimination up to 28 days post-injection [94;104].  Frangioni and colleagues correlated 
the QD size with their degree of elimination [103;105]. QD with an average diameter of 5-6 
nm, which is below the renal filtration threshold, were excreted via urine 4 hrs post-injection. 
QD of larger diameters undesirably remained in the liver, which may increase the potential 
toxicity of these nanoparticles on the long-term.  
 
The fate of QD following the different route of administrations has also been studied. 
Polymer-coated QD with an average diameter of 15-20 nm were found to migrate rapidly to 
the sentinel lymph nodes (SLN) after subcutaneous, intradermal or intraparenchymal 
injection in living animals [71-74;93]. QD migration to the lymph nodes occurred within 1-5 
min post-injection and was found selective to the first lymph node. Similar behaviour was 
observed after injecting QD of different size and surface charge properties in M21 human 
melanoma and MH-15 mouse teratocarcinoma xenograft models implanted subcutaneously in 
nude mice [95]. This observation can be advantageous in the diagnosis of cancer metastasis 
by identifying SLN residing nodules. Overall, it can be seen that QD can reside in different 
organs in living animals depending on QD characteristics (size, surface charge, and coating) 
and the route of administration. Furthermore, these studies have shown that QD can 
accumulate in the body for extensive periods of time which requires further investigation to 
identify the long-term toxicity of QD before embarking on any clinical use of QD. 
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QD  
characteristic 
 
 
QD  
colour 
 
 
QD 
 dose 
 
 
Animal/ Route of 
administration 
 
 
Aim of the study 
 
 
Methods of detection 
 
 
Main findings 
 
 
Reference 
 
 
Biodistribution 
 
       
 
PEG750, PEG3400,PEG5000-PAA-
CdSe/ZnS QD 
 
 
red 
 
360 pmol 
 
 
athymic nude mice 
( i.v) 
 
Evaluate the effect of surface 
coating on QD biodistribution 
 
Fluorescence imaging of  
living animal 
 
PEG5000 increased QD blood circulation 
and reduced liver and spleen uptake 
 
[69] 
LM-QD, BSA-QD 
 
 
red 
 
5 nmol 
 
Sprague-Dawley rats 
( i.v) 
 
 
Quantify QD tissue distribution 
 
ICP-AES 
 
- QD blood half-life was 39-59 min. 
- liver uptake 40-90%ID after 90 min 
 
 
[94] 
 
PEG5000 -CdTe/ ZnS  QD 
 
NIR 
 
40  pmol 
 
Mice 
( i.v) 
 
Assess QD fate in mice 
following i.v. injection 
 
 
 
ICP-MS 
 
QD were retained in liver & spleen with no 
urine or faecal excretion up to 28 days  
 
 
[104] 
Cysteine-coated CdSe/ZnS QD, 
99mTc-labelled  cysteine- QD 
 
 
Green-
red 
rats: 3 nmol 
mice: 300 pmol 
 
Sprague-Dawley rats 
CD-1 mice ( i.v) 
 
Evaluate QD elimination from 
the body 
Gamma counting 
 
QD with a final diameter  < 5.5 nm were  
excreted rapidly in the urine 
[103] 
MAA-coated Cd 125mTe/ZnS 
QD+mAb 201B 
 
Not 
specified 
5 g QD Balb/ c mice 
( i.v) 
Quantify in vivo  targeting 
efficiency of QD-antibody 
 
Micro SPECT/ CT,  gamma 
counting 
 
QD-antibody revealed high lung targeting 
 
[79] 
 
64Cu-DOTA PEG2000 -QD Green & 
NIR 
25 pmol Nude mice 
( i.v) 
Evaluate the biodistribution of 
commercially available QD 
Micro PET, gamma counting Rapid liver and spleen uptake regardless 
of the size or presence of surface PEG2000 
[65] 
Tumour targeting & imaging 
 
 
F3 Peptide- or , LyP-1 Peptide -
PEG5000 CdSe/ZnS QD 
 
 
Green & 
red 
 
100-200 g 
 
 
Balb/c nu/nu mice 
( i.v) 
 
Explore the feasibility of in vivo 
targeting using QD 
 
Confocal & epifluorescence 
microscopy 
 
Peptide-coated QD  specifically bound to 
the MDA-MB-435 human breast carcinoma 
vasculatures 
 
 
[52] 
PSMA-PEG5000-CdSe/ZnS QD 
 
red 0.4 nmol, 6 nmol 
 
Balb/c nude mice 
( i.v) 
Combine QD tumour targeting 
and imaging in living animals 
Fluorescence imaging of  
living animal, 
epifluorescence microscopy 
PSMA-QD showed faster and efficient 
accumulation in human prostate cancer 
(C4-2) xenograft than non-targeted QD 
 
[44] 
 
Table 1: In vivo studies of f-QD. 
 
 13 
 
PAA: polyacrylic acid; QD-LM: QD coated with mercaptoundecanoic acid crosslinked with lysine; QD-BSA: QD-LM conjugated to bovine serum albumin; ICP-AES: inductively coupled plasma atomic emission spectroscopy; ICP-MS: inductively 
coupled plasma mass spectroscopy; 99mTc: Technetium-99m; 125mTe: Tellurium -125m; MAA: mercaptoacetic acid; mAb 201B: mouse lung thrombomodulin antibody; SPECT: single photon emission computed tomography;  CT: computerised 
tomography; PET positron emission tomography;  F3: peptide preferentially binds to blood vessels and tumour cells; Lyp-1: peptide recognises lymphatic vessels and tumour cells; PSMA: prostate-specific membrane antigen; RGD: arginine-
glycine-aspartic acid; EGF: epidermal growth factor; mPEG: methoxy polyethylene glycol; i.t: intratumoural; i.d: intradermal; i.c: intracutaneous; s.c: subcutaneous; i.p: intraparenchymal; GIT: gastrointestinal tract. 
 
 
RGD-PEG2000 -CdTe QD 
 
 
 
 
 
NIR 
 
 
200 pmol 
 
 
Athymic nude mice 
( i.v) 
 
 
Non-invasive imaging of 
tumour vasculature in living 
animals using  peptide-coated 
QD 
 
 
Fluorescence imaging of  
living animal 
 
 
Only RGD-QD accumulated in the U87MG 
human glioblastoma xenograft 6 hrs post-
injection 
 
 
 
[50] 
 
 
RGD-PEG2000-CdTe QD, 
64Cu-DOTA- RGD-PEG2000-
QD 
 
 
NIR 
 
 
20 pmol 
 
 
 
Athymic nude mice 
( i.v) 
 
 
Quantify the tumour-targeting 
efficiency of QD 
 
 
 
 
 
Small-animal PET, ex vivo 
NIR fluorescence imaging 
 
 
 
RGD peptide increased QD tumour 
accumulation from <1% ID /g to 4% ID/g 
 
 
[64] 
EGF- NH2 -CdTe QD 
 
 
 
NIR 10 pmol 
 
Swiss nu/nu mice In vivo imaging of epidermal 
growth factor (EGF) receptor 
(EGFR) overexpressed on 
tumours 
In vivo and ex vivo NIR 
fluorescence imaging 
 
-Identified the phases of QD accumulation 
in colorectal HCT116 tumour 
- Only EGF-QD accumulated in the 
tumour 1-6 hrs post-injection 
 
[51] 
 
 
mPEG-CdSe/ZnS QD 
COOH- PEG QD 
NH2 –PEG QD 
 
Red & NIR 25-100 pmol Athymic nude mice 
( i.t) 
Evaluate the behaviour of QD  
injected directly into solid 
tumours 
 
Fluorescence imaging of  
living animal, necropsy 
 
All QD injected into tumour models 
migrated rapidly  to SLN 
 
[95] 
Lymph node mapping 
 
Oligomeric phosphine- coated 
CdTe QD 
 
NIR 
 
400 pmol 
10 pmol 
 
Yorkshire pigs 
SKH1 mice (i.d) 
 
 
Explore the feasibility of using  
QD in lymph node mapping 
 
 
NIR fluorescence imaging 
 
QD Localisation in SLN occurred within 3-4 
min post-injection 
 
 
 
[93] 
COOH-polymer CdTe/ZnS 
QD 
NIR 
 
8-16 pmol Athymic  mice 
( i.c, s.c.) 
Map lymphatic drainage from 
two different basins into same 
lymph node 
NIR fluorescence imaging 
 
Non-invasive and simultaneous 
visualisation of two separate lymphatic 
flows into the axillary lymph node 
 
 
[106] 
Oligomeric phosphine- coated 
CdTe QD 
NIR 200- 400 pmol 
 
 
Yorkshire pigs 
( i.p) 
 
Identify SLN following direct 
injection in the organ 
Intraoperative NIR 
fluorescence imaging 
Mapping the SLN of the lung, oesophagus, 
pleural space and GIT 
 
 
[71-74] 
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6. QD toxicity  
QD have been applied to molecular biology due to their brighter fluorescence and higher 
photostability, however potential concerns about the QD toxicity have risen, caused by the 
well-known toxicity of cadmium and selenium, the physicochemical properties of the surface 
coat, and QD small size that provides large surface area that would interact with different 
biological molecules [100;107-109]. Potential routes for QD exposure are environmental, 
workshops, therapeutics, and diagnostics. Few studies reported that QD nanoparticles could 
be inhaled and deposited in the respiratory passages depending on their sizes [107;110]. Also, 
it has been shown that QD are capable of penetrating the skin barrier [111-113] and can cause 
inflammation and irritation in epidermal keratinocytes in vitro after long-term exposure 
(48hours) [114]. These preliminary studies suggest extra care to be taken, as systemic QD 
toxicity can happen via inhalation and direct skin contact, especially during the QD 
production step.  
 
QD toxicity in vitro: The toxicity of QD is mainly derived from their intrinsic core 
composition such as CdSe and CdTe. Cd+2 ions have been shown to be toxic upon their 
release from the QD core due to photolysis and/or oxidation [4]. Other mechanisms 
contributing to QD-induced cytotoxicity (Figure 2) have also been identified including the 
formation of reactive oxygen species (ROS) tha§t induce cell damage [41]; the interaction of 
QD nanoparticles with the individual cell components (e.g DNA or proteins) or with the cell 
membrane  [115]. QD-induced cell dysfunction is accompanied by apoptotic and necrotic 
biochemical changes including: morphological alteration in the plasma membrane; 
mitochondria and nucleus damage [41]; lysosome enlargement [116]; reduction in 
cytochrome C concentration [41;116;117]; loss of mitochondrial membrane potential [117]; 
and upregulation of peroxidised lipids [118].  
 
The correlation between cytotoxicity and free Cd2+ ions has been established [4;115;119] 
with the occurrence of significant cell death in the range of 100 M to 400 M Cd2+ ions [4]. 
The blue-shift in QD fluorescence spectrum was observed as a sign of QD size reduction and 
Cd2+ release [4;120]. In addition, QD-induced cytotoxicity dramatically increased in the case 
of QD exposure to oxygen or ultraviolet (UV) light [4;41]. The concept of QD phototoxicity 
has been exploited in photodynamic therapy as previously mentioned [84;86;88-90]. Several 
 15 
attempts to reduce QD toxicity have also been described. For instance, ZnS coating protects 
the QD core from oxidation, which minimises Cd+2 leakage and reduces the QD-induced 
cytotoxicity [109;116;119]. In addition, the use of antioxidants, such as N-acetylcysteine 
(NAC) has been shown to be effective in reducing QD cytotoxicity. 
 
In general, most cytotoxicity studies used QD solubilised by direct exchange of the organic 
coat (TOPO) with hydrophilic ligands, such as mercaptopropionic acid (MPA-QD) 
[41;42;109;121], mercaptoacetic acid (MAA-QD) [4], mercaptoundecanoic acid (MUA-QD) 
[42], cysteamine (QD-NH2) [109;116] and thioglycerol (QD-OH) [109]. However, ligand 
detachment from the QD surface may occur due to the weak interaction between the QD 
surface and the ligands [38;122], especially under unfavourable conditions like those in the 
endosomal compartment [10]. Several studies have indicated that cell incubation with QD 
solubilised by surface ligand exchange was mostly associated with severe cell death with 
increasing QD concentrations, similar to that induced by Cd2+ ions [4;41;115;116;121], 
which indiciets the need for  more stable QD.  
  
Hoshino et al. reported that no evidence of Cd2+ induced cytotoxicity was identified once 
ZnS coating was used [109]. Kirchner et al. showed that PEG coating greatly improved 
CdSe/ZnS QD toxicity profiles [115]. PEG-silica coated QD, which were fabricated by 
embedding the CdSe/ZnS QD in a shell of cross-linked silica molecules and then conjugated 
with PEG were shown to be non-toxic up to 30 M in Cd+2 surface concentration [119]. 
Similar to this, Pellegrino et al. demonstrated that silica-coated QD (silanised) were highly 
resistant to chemical and metabolic degradation [123]. Furthermore, conjugating peptides to 
silanised CdSe/ZnS QD showed low cytotoxicity even once translocated to the cell nucleus 
[124]. Zhang et al. investigated the genotoxicity of PEG-silica coated QD in human skin 
fibroblast (HSF-42) cells exposed to QD dose between 8 nM and 80 nM, verifying that PEG-
silica coated QD were non-toxic even at the gene level [125]. Overall, the cytotoxicity studies 
carried out so far have shown that the key determinants of QD toxicity are the composition 
and functionalisation. However, other factors including cell type [42], QD size [121], and QD 
exposure to oxygen and UV light [4] were also found to influence QD cytotoxicity.                                                                                                                                                                                                       
 
 QD toxicity in vivo: The concern about the potential toxicity of QD in vivo is growing due 
to the well-established toxicological profile of cadmium, the physicochemical characteristics 
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of certain QD surface coatings, and the size of QD. In general, the small size of nanoparticles 
provides a large surface for interaction with different biological molecules [107;109]. 
Moreover, nanoparticles of few nanometers in size can enter vital organs such as heart, lung, 
and brain following intravenous administration.  Therefore, studies that will help determine 
the QD toxicity in vivo are highly required.  
 
Information about QD toxicity were initially obtained by alternative models of more complex 
organisms. Xenopus embryos [22] and zebrafish embryos [19] are some of the most sensitive 
models in which QD toxicity has been tested. Zebrafish embryos and Xenopus embryos 
microinjected with 1108 QD/cell and 2109QD/cell, respectively, did not exhibit any sign of 
toxicity. However, both Zebrafish and Xenopus embryos exhibited abnormalities as the doses 
were increased to 2108 QD/cell and 5109QD/cell, respectively. This is thought to be due to 
either the intrinsic toxicity of QD or the osmotic equilibrium changes [22].  
 
Several groups have injected QD in animals for targeting and imaging purposes. However, 
very few studies reported QD toxicity in living animals. QD injected systemically (via tail 
vein or jugular vein) in mice and rats (pmol-nmol range), showed no apparent toxicity several 
months post-injection [20;94;95]. Other studies have shown that 200-400 pmol of near- 
infrared (NIR) QD were injected locally to map the sentinel lymph nodes (SLN) into 
Yorkshire pigs, no changes in the heart rate, blood pressure, and oxygen level were observed 
during the experimental procedure and after several hours [71-74;93]. The low toxicity 
observed in these latter studies was expected since the QD were injected locally and in most 
cases the injected site (tumour and SLN) was removed by the end of the surgical procedure.  
 
 
 
5. CONCLUSION 
Semiconductor nanocrystals are tiny light-emitting nanoparticles with a mean diameter of 1 
to 20 nm. They are generally composed of a semiconductor core covered with a shell of a 
second semiconductor material, mainly ZnS. QDs offer many advantages in comparison to 
conventional organic dyes such as bright photoluminescence, narrow symmetric emission, 
broad excitation spectrum, and high photostability. The diversity of QD composition, size 
and surface functionalisation results in their versatile applications. They can be made very 
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effective for cellular and in vivo imaging by coupling with targeting ligands such as, proteins, 
peptides or antibodies. The photogeneration of free radicals by QDs is experimentally used in 
photodynamic therapy. Interestingly, the in vivo behaviour is be easily manipulated by 
modulating the particle size and surface coating, which impact QD blood circulation, organ 
distribution, excretion and toxicity.  
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